“We also remain on track to begin patient enrollment in the fourth quarter for several important clinical trials that will support a steady cadence of future product launches.”

In context

“quarter results, and updated outlook for the remainder of the year, we are reaffirming our full year guidance for comparable sales growth of 6.5% to 7.5% and raising our EPS guidance range to $5.45 to $5.60 Before summarizing our second quarter results, I want to highlight a few recent pipeline achievements, including completing patient enrollment in our tectonic coronary IVL pivotal trial, completing our FDA submission for approval of our new Amulet 360 left atrial appendage device obtaining CE Mark for Libre Duo the world's first dual glucose ketone monitoring sensor designed to detect rising ketone levels and help prevent diabetic ketoacidosis. We anticipate launching these 3 new products. Along with our Tactiflex Duo PFA catheter in the US at a steady cadence over the next 12 months. We also remain on track to begin patient enrollment in the fourth quarter for several important clinical trials that will support a steady cadence of future product launches. And these include a balloon expandable TAVR valve, a leadless conduction system pacing device, leveraging our Avera pacemaker, a mitral replacement valve developed following acquisition of Cephea Valve Technologies. A peripheral IVL device developed following the acquisition of CSI, and a wearable continuous lactate monitoring sensor designed to reduce the risk of sepsis following discharge from the hospital. I will now review our second quarter results in more detail before I turn the call over to Philip, and I will start with diagnostics. Diagnostic test results inform approximately 70% of all health care decisions. Making testing volumes a reliable barometer of overall health care activity and demand. Our test volume data that is sourced directly from our diagnostic instruments located”